e-learning
resources
European Respiratory Review
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
Arnaud Boyer, Eddy Pasquier, Pascale Tomasini, Joseph Ciccolini, Laurent Greillier, Nicolas Andre, Fabrice Barlesi, Celine Mascaux
Source:
Eur Respir Rev, 27 (147) 170098; 10.1183/16000617.0098-2017
Journal Issue:
March
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Arnaud Boyer, Eddy Pasquier, Pascale Tomasini, Joseph Ciccolini, Laurent Greillier, Nicolas Andre, Fabrice Barlesi, Celine Mascaux. Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?. Eur Respir Rev, 27 (147) 170098; 10.1183/16000617.0098-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Immunotherapy for malignant pleural mesothelioma: ready for clinical practice?
Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies?
Year: 2016
Malignant pleural mesothelioma: new treatments, new hopes?
Source: Eur Respir J , 49 (3) 1700319; DOI: 10.1183/13993003.00319-2017
Year: 2017
Volatile organic compounds as an early diagnostic tool for malignant pleural mesothelioma
Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma
Year: 2014
Multimodal management of malignant pleural mesothelioma: where are we today?
Source: Eur Respir J 2014; 44: 754-764
Year: 2014
Pleurodesis for malignant pleural effusion: which compound?
Source: Hands-on Course 2013 - Medical Thoracoscopy
Year: 2013
Pleurodesis for malignant pleural effusion: which compound?
Source: Hands-on Course 2012 - Medical Thoracoscopy
Year: 2012
Management of malignant pleural mesothelioma in 2017
Source: ERS Skills course - Medical thoracoscopy
Year: 2017
Volatile organic compounds increase the likelihood of detecting malignant pleural mesothelioma
Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management
Year: 2015
Management of malignant pleural mesothelioma
Source: Hands-on Course 2012 - Medical Thoracoscopy
Year: 2012
Management of malignant pleural mesothelioma
Source: ERS Course 2016 - Skills course on medical thoracoscopy
Year: 2016
Management of malignant pleural mesothelioma
Source: School Course 2014 - Medical Thoracoscopy
Year: 2014
Management of malignant pleural mesothelioma
Source: Hands-on Course 2013 - Medical Thoracoscopy
Year: 2013
Management of malignant pleural mesothelioma
Source: ERS Skills Course 2015
Year: 2015
Exhaled breath to screen for malignant pleural mesothelioma: a validation study
Source: Eur Respir J, 50 (6) 1700919; 10.1183/13993003.00919-2017
Year: 2017
Non-malignant pleural disease from asbestos and malignant pleural mesothelioma
Source: Eur Respir Monogr 2020; 89: 141-149
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept